News | June 11, 2009

Covidien to Highlight Technetium-99m Development at SNM

June 12, 2009 - Covidien will be highlighting at the 2009 SNM Annual Conference in Toronto, June 13-17, its abbreviated new drug application (ANDA) for its kit for the preparation of technetium-99m (Tc-99m) sestamibi injection and radiosotope development.

Covidien's generic product is pharmaceutically equivalent to Cardiolite1, a myocardial perfusion imaging agent used for detecting coronary artery disease. With FDA approval of the ANDA, which was filed by the company's Mallinckrodt subsidiary, Covidien's generic product is now available for customers in the United States.

Covidien's will also focus on its co-marketing agreement with Siemens' PETNET to offer high and low energy radioisotopes to nuclear medicine sites. Through the agreement, Coviden Imaging Solutions and PETNET created a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radioisotopes, designed to illuminate conditions such as cancer or heart disease when doing SPECT and PET scans.

It will also underscore its agreement with Bacock & Wilcox Technical Services Group Inc. to develop technology for the manufacture of molybdenum-99 (Mo-99), the parent isotope of Tc-99m, the most widely used radioisotope for molecular imaging and nuclear medicine procedures. This collaboration is an initial step toward establishing a large-scale U.S. supply of medical isotopes.

For more information: www.covidien.com

Related Content

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media| October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
MR angiography, MRA, Bayer, Gadavist, gadobutrol injection, FDA approval, supra-aortic arteries
Technology | Contrast Media| April 29, 2016
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use...
Overlay Init